Shopping Cart
- Remove All
Your shopping cart is currently empty
BMS-8
Catalog No. T26859Cas No. 1675201-90-7
BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.
BMS-8
Catalog No. T26859Cas No. 1675201-90-7
BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $33 | In Stock | |
| 5 mg | $76 | In Stock | |
| 10 mg | $133 | In Stock | |
| 25 mg | $283 | In Stock | |
| 50 mg | $455 | In Stock | |
| 100 mg | $672 | In Stock | |
| 500 mg | $1,430 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $96 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "BMS-8"
LSD1-IN-24
T678714734-59-2
LSD1-IN-24 is a selective and potent LSD1 inhibitor with an IC50 value of 0.247 μM.LSD1-IN-24 induces PD-L1 expression and enhances the T cell killing response, and can be used in cancer-related diseases.
- $52
Size
QTY
Sulfamethoxypyridazine
CL 13494
T084480-35-3
Sulfamethoxypyridazine (CL 13494) is a sulfanilamide antibacterial agent.
- $42
Size
QTY
BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride
T40111L2691796-83-3In house
BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride, a resorcinol di-Ph ether scaffold-based programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor, inhibits the PD-1/PD-L1 interaction with an IC50 of 39.2 nM. It contains the target protein PD-1/PD-L1 ligand and PROTAC linker, which can be used to synthesize PROTAC PD-1/PD-L1 degrader-1 and has anticancer activity. Additionally, it serves as a diluent for the preparation of tablets for direct compression.
- $189
Size
QTY
PD-1/PD-L1-IN-9
T96512628506-54-5In house
PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in vivo in a CT26 mouse model.
- $55
Size
QTY
PD-L1-IN-3
T793142953044-29-4
PD-L1-IN-3 (Compound 4a) functions as an inhibitor of the PD-1/PD-L1 axis, with an IC50 value of 4.97 nM for PD-L1 inhibition and an EC50 value of 2.70 μM for Jurkat T cell modulation. It antagonizes the PD-1/PD-L1 interaction by binding to the PD-L1 dimer, obstructing PD-1 signaling. This compound is utilized in research pertaining to lung cancer and melanoma [1].
- $90
Size
QTY
LSD1-IN-27
T776352904571-94-2
LSD1-IN-27 is a potent LSD1 inhibitor with an IC50 value of 13 nM.LSD1-IN-27 inhibited the stemness and migration of gastric cancer cells.LSD1-IN-27 inhibited the expression of PD-L1 in BGC-823 and MFC cells.LSD1-IN-27 potentiated the T-cell immune response against gastric cancer.
- $158
Size
QTY
IMMH 010 maleate
YPD-30 maleate
T839702541982-47-0In house
IMMH 010 maleate (YPD-30 maleate) is an orally available programmed cell death ligand 1 inhibitor with potential antitumor activity for the study of neurological disorders and advanced malignant solid tumors.
- $195
Size
QTY
PD-1-IN-22
T123792349372-98-9In house
PD-1-IN-22 is a potent inhibitor of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction, with an IC50 of 92.3 nM.
- $117
Size
QTY
BMS-1
Cited
PD1-PDL1 inhibitor 1, PD-1/PD-L1 inhibitor 1
T36551675201-83-8
BMS-1 (PD-1/PD-L1 inhibitor 1) is an inhibitor of the PD1-PD-L1 protein-protein interaction. It also acts as an immunomodulator. Programmed death ligand 1 (PD-L1) is a protein in humans that is encoded by the CD274 gene and the upregulation of PD-L1 allows Ys to evade the host immune system. High tumor expression of PD-L1 was associated with increased tumor aggressiveness and a 4.5-fold increased risk of death.
- $48
Size
QTY
CitedBMS-202 Cited
PD1-PDL1 inhibitor 2, PD-1/PD-L1 inhibitor 2
T31461675203-84-5
BMS-202 (PD1-PDL1 inhibitor 2) is an inhibitor of the PD-1 (Programmed death- 1) /PD-Ll (Programmed death-ligand 1) protein/protein interaction.
- $57
Size
QTY
CitedPD-1/PD-L1-IN-10
T96162487550-41-2
PD-1/PD-L1-IN-10 is an orally available PD-1/PD-L1 inhibitor (IC50 value of 2.7 nM) that shows anti-tumor activity.
- $44
Size
QTY
Tomivosertib Cited
eFT508
T34681849590-01-7
Tomivosertib (eFT508) is a potent and highly selective MNK1 and MNK2 inhibitor with an IC50 value of 1-2 nM.
- $59
Size
QTY
CitedSelect Batch
Purity:99.06%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers. |
| Targets&IC50 | PD-1/PD-L1:7.2 μM |
| In vitro | BMS-8 demonstrates a more stable binding affinity for one PD-L1 monomer compared to another, with its ability to induce PD-L1 dimerization further enhanced by non-polar interactions involving Ile54, Tyr56, Met115, Ala121, and Tyr123 on each monomer, in addition to the involvement of water-mediated bridges at ALys124[2]. |
| Molecular Weight | 494.42 |
| Formula | C27H28BrNO3 |
| Cas No. | 1675201-90-7 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/ml (121.35 mM)  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy BMS-8 | purchase BMS-8 | BMS-8 cost | order BMS-8 | BMS-8 chemical structure | BMS-8 in vitro | BMS-8 formula | BMS-8 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.